Collectively, our findings indicate that HER2+ BC tumors resistant to anti-HER2 mAbs display upregulated CAF-S1/pCAF/FAP expression as well as reduced immune cells abundance and low IL2 activity. The gene discussed is IL2; the disease is breast cancer.